Craig-Hallum raised the firm’s price target on GeneDx (WGS) to $114 from $95 and keeps a Buy rating on the shares. Q4 results demonstrate the potential for significant earnings power over time and the 2025 revenue guidance “seems conservative” given an expanding set of near, mid, and long-term growth drivers, the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- Delta flight crashes in Toronto, Southwest cuts corporate roles: Morning Buzz
- GeneDx reports FY24 EPS ($1.94) vs. ($7.23) last year
- GeneDx sees FY25 revenue $350M-$360M, consensus $338.77M
- WGS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- GeneDx selloff after short report ‘appears overdone,’ says Wells Fargo
Questions or Comments about the article? Write to editor@tipranks.com